Tianda Pharmaceuticals Limited announced that it has recently put its new R&D and production base located in the Biomedicine Industrial Park in the Jinwan District of Zhuhai (the "Zhuhai Base") into production. It is poised to become a pharmaceutical and health industry base with high standard, quality and efficiency. The Zhuhai Base covers a total area of 96,000 square meters, with an investment of RMB 390 million for the first phase of the development.

The Company attaches great importance to innovation and R&D, and owns a number of invention patents. One of the products, the Valsartan capsules, which was rated as a famous high-tech product of Guangdong Province and a winner of the China Patent Award, passed the conformance assessment in 2020 and subsequently came in first place in the nation's Third Round of Centralized Drug Procurement with Target Quantity. The Company has secured nationwide distribution for this product.

The Company continues to implement the strategies of "development of Chinese medicine as foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services", endeavouring to speed up product introduction and R&D, and boost business expansion and investment mergers and acquisitions. It strives to be a leading pharmaceutical enterprise setting its footholds in China and seeking to expand its presence worldwide.